Pharmaceuticals giant GlaxoSmithKline suffered an unprecedented defeat at its annual general meeting when shareholders won a vote against a multi-million pound pay and rewards package for executives.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...

KARACHI: PSO proudly celebrated the success of its Shaheen Program, a ground-breaking initiative designed to promote women's mobility. This pioneering initiative empowers women with comprehensive ...

GSK’s Blenrep combos are being reviewed in 14 nations. Credit: Magda Wygralak/Shutterstock. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for ...

The British multinational pharmaceutical and biotechnology company GSK has officially opened its new regional vaccine distribution centre in Abu Dhabi to serve the demand across the Gulf ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Today, a brief rundown of news involving GSK and Bristol Myers Squibb, as well as updates from Elevation Oncology, Bayer and Airna that you may have missed. Novartis’s deal for Regulus is its second ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

A draft budget document shows the Trump administration’s plan to slash funding to the Department of Health and Human Services includes substantial cuts to the Food and Drug Administration. The ...

Sattar has consulted for and/or received speaker honoraria from Abbott, AbbVie, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GlaxoSmithKline, Hanmi ...

The UK on Thurs­day au­tho­rized GSK’s Blenrep to treat cer­tain mul­ti­ple myelo­ma pa­tients in two dif­fer­ent reg­i­mens, mark­ing the drug’s first ap­proval world­wide ...